Zobrazeno 1 - 10
of 248
pro vyhledávání: ''
Autor:
Yukyung Jun, Yun-Suhk Suh, SungHee Park, Jieun Lee, Jong-Il Kim, Sanghyuk Lee, Wan-Ping Lee, Olga Anczuków, Han-Kwang Yang, Charles Lee
Publikováno v:
Cancer Research. 82:543-555
Alternatively spliced RNA isoforms are a hallmark of tumors, but their nature, prevalence, and clinical implications in gastric cancer have not been comprehensively characterized. We systematically profiled the splicing landscape of 83 gastric tumors
Autor:
Paola Suarez-Meade, Rachel Sarabia-Estrada, Karim ReFaey, Paula Schiapparelli, Cesar A. Garcia, Matija Snuderl, Mieu Brooks, Erik H. Middlebrooks, Sujan Kumar Mondal, Mark E. Jentoft, Adip G. Bhargav, Hugo Guerrero-Cazares, Natanael Zarco, Alfredo Quinones-Hinojosa, Anna Carrano
Publikováno v:
Mol Cancer Ther
Glioblastoma (GBM) is the most common primary brain cancer in adults where tumor cell heterogeneity and sex differences influence clinical outcomes. Here, we functionally characterize three male and three female patient-derived GBM cell lines, identi
Autor:
Shengbao Suo, Adrienne M. Luoma, Nathanael S. Gray, Julia McCreary, Sara M. Tolaney, Kelly Boelaars, Max Heckler, Eleanor Clancy-Thompson, Kai W. Wucherpfennig, Guo-Cheng Yuan, Tamara Boschert, Thorsten R. Mempel, Michael Dougan, Stephanie K. Dougan, Kevin Roehle, Lestat R. Ali, Henry W. Long, Patrick J Lenehan, Shom Goel, Vera Peters, Li Qiang, Francesco Marangoni, Katherine S. Ventre, Eric S. Wang
Publikováno v:
Cancer discovery, vol 11, iss 10
Cancer Discov
Cancer Discov
CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in mouse and human CD8+ T cells during early stages of activation. Mice receiving tumor-specific CD8+ T cells treated with C
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Takuro Matsumoto, Prajwal Neupane, Aung Kyi Thar Min, Motonobu Saito, Katsuharu Saito, Tomoyuki Momma, Zenichiro Saze, Shinji Ohki, Naoto Yamauchi, Suguru Hayase, Hiroshi Nakano, Hirokazu Okayama, Eisei Endo, Leo Yamada, Kosaku Mimura, Hiroyuki Hanayama, Yasuyuki Kanke, Yohei Watanabe, Hiromasa Ohira, Shotaro Nakajima, Koji Kono, Koji Kase, Akinao Kaneta
Publikováno v:
Molecular Cancer Research. 19:1085-1095
The tumor microenvironment (TME) plays a key role in the efficacy of neoadjuvant chemotherapy (NAC) in solid tumors including esophageal squamous cell carcinoma (ESCC). However, the TME profile of ESCC treated with NAC is not fully understood. In thi
Autor:
Takahiro Kodama, Yuta Myojin, Daisuke Motooka, Yu Sato, Ayumu Taguchi, Ryotaro Sakamori, Kazuki Maesaka, Satoshi Tanaka, Tetsuo Takehara, Kazuyoshi Ohkawa, Hayato Hikita, Tomohide Tatsumi, Yoshito Hayashi, Hidetoshi Eguchi, Yuichi Abe, Eiji Mita
Publikováno v:
Clinical Cancer Research. 27:1150-1161
Purpose: Hepatocellular carcinoma (HCC) is characterized by high intertumor heterogeneity of genetic drivers. Two multitarget tyrosine kinase inhibitors (TKI), lenvatinib and sorafenib, are used as standard-of-care chemotherapeutics in patients with
Autor:
Daniel W. Sherbenou, Thomas G. Martin, Olivia Perez De Acha, Byron Hann, Blake T. Aftab, Megan Murnane, Yang Su, Jeffery L. Wolf, Shelby C. Bearrows, Bin Liu, Christopher R. Behrens
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 22
Clin Cancer Res
Clin Cancer Res
Purpose: New therapies have changed the outlook for patients with multiple myeloma, but novel agents are needed for patients who are refractory or relapsed on currently approved drug classes. Novel targets other than CD38 and BCMA are needed for new
Autor:
Yutaka Kawakami, Kenjiro Kosaki, Eiji Sugihara, Norisato Hashimoto, Tomonori Yaguchi, Takaaki Sato, Shinichiro Okamoto, Hideyuki Saya, Satoru Osuka, Sayaka Ueno, Shogo Okazaki, Takatsune Shimizu
Publikováno v:
Cancer Research. 80:4439-4450
Death receptor Fas-mediated apoptosis not only eliminates nonspecific and autoreactive B cells but also plays a major role in antitumor immunity. However, the possible mechanisms underlying impairment of Fas-mediated induction of apoptosis during lym
Autor:
Thai H. Ho, Kenneth M. Boucher, Timothy Sargis, Jeffrey Mohlman, Deepika Sirohi, Christopher G. Wood, Adela Ramirez-Torres, Archana M. Agarwal, Lyska Emerson, Neeraj Agarwal, Pheroze Tamboli, Benjamin T. Spike, Rebecca S. S. Tidwell, Benjamin L. Maughan, Guillermina Garcia, Eric Jonasch, Sophie Cowman, Sheryl R. Tripp, Adam A. Olalde, Christopher J. Conley, Mei Yee Koh, Miekan A Stonhill, Neelima Kandula, Xian De Liu, Kanishka Sircar, Daniel Fuja, Jose A. Karam
Publikováno v:
Clin Cancer Res
Purpose: Clear cell renal cell carcinoma (ccRCC) is frequently associated with inactivation of the von Hippel–Lindau tumor suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-based st
Autor:
Alessandro Cavaliere, Michaela Deiana, Camilla Zecchetto, Davide Melisi, Raffaela Santoro, Sara Lonardi, Geny Piro, Domenico Mangiameli, Vita Fedele, Diana Bazan, Francesca Simionato, Valeria Merz, Maria Teresa Valenti, Fabio Sabbadini
Publikováno v:
Clinical Cancer Research. 26:4661-4669
Purpose: Pancreatic cancer is one of the most lethal solid tumors, mainly because of its intrinsic chemoresistance. We identified TAK1 as a central hub sustaining this resistance. Nanoliposomal irinotecan (nal-IRI) is a novel treatment for metastatic